Company Profile
AtriCure Stock Price, News & Analysis
- Ticker:
- ATRC
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
39.49 USD (+0.38%)
Close
Last updated: August 6, 2026
1.31B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ATRC closed up 0.38% at $39.49. No new same-company headline was identified in the current news window.
Company overview
Atrial Fibrillation Surgery
AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm.
Ablation Technologies
The Isolator Synergy Ablation System is FDA approved for persistent atrial fibrillation and anchors AtriCure’s surgical ablation portfolio. The company also offers the Hybrid AF Therapy, a minimally invasive approach for patients with long-standing persistent atrial fibrillation.
Adjacent Surgical Markets
AtriCure’s broader portfolio includes left atrial appendage management and post-operative pain-management products. These complementary technologies allow the company to serve multiple needs within cardiac and thoracic surgery using a common physician and hospital customer base.
Future catalysts
AtriCure's catalysts are AF ablation adoption, left-atrial appendage management, and continued procedure growth in cardiac surgery. The company improves when its installed physician base keeps converting into repeatable use.
Recent news
- 01
AtriCure to Participate at Upcoming Investor Conferences
Source: AtriCure
- 02
AtriCure Reports Second Quarter 2026 Financial Results
Source: AtriCure
- 03
AtriCure to Announce Second Quarter 2026 Financial Results
Source: AtriCure
- 04
- 05
AtriCure Reports First Quarter 2026 Financial Results
Source: AtriCure
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AtriCure (ATRC)?
AtriCure (ATRC) most recently closed at 39.49 USD, a +0.38% move versus the previous session.
What is the market cap of AtriCure (ATRC)?
AtriCure currently has a market capitalization of 1.31B USD on BioPharmSignal.
What does AtriCure do?
Atrial Fibrillation Surgery AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm. Ablation Technologies The Isolator Synergy Ablation System is FDA approved...
On which exchange is ATRC stock listed?
AtriCure (ATRC) is associated with NASDAQ, United States, MedTech.
What is Atrial?
AtriCure's catalysts are AF ablation adoption, left-atrial appendage management, and continued procedure growth in cardiac surgery.
Which conditions is AtriCure targeting with Atrial?
AtriCure's catalysts are AF ablation adoption, left-atrial appendage management, and continued procedure growth in cardiac surgery.
How does AtriCure describe recent progress with Atrial?
AtriCure's catalysts are AF ablation adoption, left-atrial appendage management, and continued procedure growth in cardiac surgery.
What is Fibrillation?
Atrial Fibrillation Surgery AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation.